The Vitiligo Treatment Market Size was valued at USD 1.5 billion in 2022. The Vitiligo Treatment market industry is projected to grow from USD 1.593 billion in 2023 to USD 2.57 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.20% during the forecast period (2023 - 2032). Increased awareness among the population and the increasing number of clinical trialsare the key market drivers enhancing market growth.
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
When pigment-producing cells pass away or stop working, vitiligo develops. The mouth, hair, palms, neck, and eyes are just a few body parts that might suffer from loss of skin color. It results from the skin's lack of a pigment called melanin. The pigment melanin, made by melanocytes, which are skin cells, imparts color to the skin. The global increase in vitiligo patients is one of the major drivers of the expansion of the vitiligo treatment market. The emergence of technology that provides medications for controlling various issues brought on by disease and the predominance of government investment in healthcare infrastructure enhance the market's growth.
However, it is anticipated that market growth will be constrained by the expense of vitiligo evaluation and therapy and concerns regarding branded drugs' patent expirations. Due to the arrival of generic medications and the low healthcare spending in many developing nations, the marketplace for vitiligo treatments will likely face difficulties throughout the forecast period. Lack of functioning melanocytes prevents your skin from producing enough melanin when you have vitiligo. This results in the formation of white patches on the surface of the skin or hair. Although vitiligo does not negatively affect a patient's health, it can cause physical issues, including sunburn, hearing loss, and eye and ear problems. The need for novel and cutting-edge therapies to control vitiligo, which results in a significant loss of skin pigmentation, is always growing. To increase the effectiveness and results of therapy in the patient population, market participants are continually concentrating on discovering innovative vitiligo treatment alternatives. This is projected to cause the market for vitiligo treatments to expand.
A brand-new $3.75 million project, coordinated by the University of Massachusetts Chan Medical School, will investigate potential risk factors for vitiligo. A total of 1,000 participants are expected to join the trial, of whom 200 are expected to have vitiligo. The remainder of the participants will be members of at-risk families, of which 40 to 60 are anticipated to acquire vitiligo over the study's five-year duration. The researchers claim the study's unique feature—complete remote execution—is unmatched. Enrolled individuals will get kits for collecting blood, saliva, and skin tissue samples in the mail every six months. Each participant's saliva is going to be genetically sequenced. Negative pressure is used in an at-home serum and blood collection platform created by Tasso to draw plasma without using syringes or venipunctures. The blood samples will be genotyped and analyzed for antibodies and other biomarkers.
A large patient pool is ly suffering from vitiligo. The increasing awareness regarding the disease and the subsequent need for advanced and effective treatment options drive the growth of the vitiligo treatment market. Currently, there is no approved treatment option for vitiligo, which has led to increasing demand for vitiligo treatment options in both developed and developing markets. According to the American Academy of Dermatology (AAD), an estimated 84.5 million, or one in four Americans, suffer from vitiligo. Also, in the existing vitiligo treatment options, there need to be more effective treatment options, which can often lead to the relapse of vitiligo in the patches of skin previously treated. These factors, combined with the strong R&D pipeline of new vitiligo treatment options of key market players, are major factors driving the market in 2018. However, lack of awareness among the patient population regarding vitiligo treatment in emerging countries, combined with long procedures for regulatory approvals, are factors limiting the growth of market CAGR.
Additionally, there is a significant rise in beauty consciousness among consumers owing to the growing awareness about different aesthetic treatments, increasing per capita income, and adoption of digital platforms. According to the International Society of Aesthetic Plastic Surgery (ISAPS), there was a 27.3% growth in worldwide total non-surgical procedures. In addition, according to the American Society of Plastic Surgeons (ASPS), the number of minimally invasive aesthetic procedures increased by about 200% during 2000-2018. Moreover, about 15.9 million minimally invasive cosmetic procedures were performed in 2019, a 2% rise compared to 2018. Thus, the increasing geriatric population also drives the demand for minimally invasive cosmetic procedures.Thus,these factors drive the Vitiligo Treatment market revenue.
The Vitiligo Treatment market segmentation, based on type, includes non-segmental and segmental vitiligo. The non-segmental vitiligo segment dominated the market due to a rise in patients diagnosed with non-segmental vitiligo. In addition, it is the fastest-growing segment between 2022-2031 due to increased awareness about the symptoms and causes of vitiligo.
Figure 1 Vitiligo Treatment Market, by Type, 2022 & 2032 (USD billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Vitiligo Treatment market segmentation, based on treatment type, includes therapy, surgery, and medication. The medication segment dominated the market because it is the most widely used and preferred treatment option for vitiligo due to its ease of use and availability.
Based on end-user, the Vitiligo Treatment market segment includes hospitals and aesthetic clinics. The hospital segment dominated the market because hospitals are typically the primary healthcare facilities where patients seek treatment for vitiligo, especially in cases where the condition is severe or widespread.A cream to aid in repigmentation will soon be available to patients in the UK with non-segmental vitiligo thanks to the Medicines and Healthcare Products Regulatory Agency's (MHRA) approval for marketing the product. After receiving permission from the US Food and Drug Administration, or FDA, and the European Commission (EC), Incyte Biosciences of the US, maker of Opzelura (ruxolitinib), is currently marketed as a prescription cream for autoimmune conditions in both the US and Europe. Opzelura is the first medication authorized in the UK for treating repigmentation in non-segmental vitiligo, according to Incyte. Patients with non-segmental facial vitiligo above 12 will be eligible to purchase Opzelura.
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American vitiligo treatment market area will dominate this market due to increased awareness, the availability of medications, and the rise in vitiligo in adults. The high prevalence of vitiligo is a growing healthcare sector in this Region. In addition, the growing number of established health clubs and fitness facilities will boost the market growth in this Region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 VITILIGO TREATMENT MARKET SHARE BY REGION 2022 (%)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's Vitiligo Treatment market accounts for the second-largest market share due to the rising adoption of cutting-edge technology and increased novel surgical techniques by key players. Further, the German Vitiligo Treatment market held the largest market share, and the UK Vitiligo Treatment market was the fastest-growing market in the European Region.
The Asia-Pacific Vitiligo Treatment Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due todue to rise in healthcare expenditure and the rise in research and development activities in the pharmaceutical sector. Moreover, China’s Vitiligo Treatment market held the largest market share, and the Indian Vitiligo Treatment market was the fastest-growing market in the Asia-Pacific region.
Vitiligo Treatment Key Market Players& Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Vitiligo Treatment market grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The vitiligo treatment industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Vitiligo Treatment industry to benefit clients and increase the market sector. In recent years, the Vitiligo Treatment industry has offered some of the most significant medical advantages. Major players in the Vitiligo Treatment market, including Incyte (US), Koninklijke Philips N.V. (Netherlands), Bausch Health Companies Inc. (Canada), Dr. Reddy's Laboratories Ltd. (India), STRATA Skin Sciences(US), Clinuvel Pharmaceuticals Ltd (Australia), Roivant Sciences Ltd. (Switzerland), ISSAR Pharmaceuticals Pvt. Ltd.(India) Kernel Medical Equipment Co., LTD. (China), and LightSource (US)., and others are attempting to increase market demand by investing in research and development operations.
Strata Skin Sciences is an American medical device company focused on designing, developing, and commercializing non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. STRATA Skin Sciences, a medical technology company dedicated to developing, commercializing, and marketing innovative products to treat various autoimmune skin diseases, announced that it had joined the  Vitiligo Foundation as a corporate sponsor (GVF).
Celgene merged with Bristol Myers Squibb creating a leading biopharma company ideally positioned to discover, develop and deliver innovative medicines for patients fighting serious diseases.Bristol-Myers Squibb acquired Celgene for $74 billion.
Key Companies in the vitiligo treatment market include
Vitiligo Treatment Industry Developments
April 2022 Incyte and Maruho Co., Ltd. announced a Strategic Alliance Agreement for the development, manufacturing, and exclusive commercialization of ruxolitinib cream, a novel cream formulation of Incyte’s selective JAK2 inhibitor ruxolitinib, in Japan for the treatment of autoimmune and inflammatory dermatology indications.
March 2022Â STRATA Skin Sciences, a medical technology company dedicated to developing, commercializing, and marketing innovative products for treating various autoimmune skin diseases, announced that it had joined the Vitiligo Foundation as a corporate sponsor (GVF).
| Report Attribute/Metric | Details |
| Market Size2022 | USD 1.5billion |
| Market Size 2023 | USD 1.593billion |
| Market Size2032 | USD 2.57billion |
| Compound Annual Growth Rate (CAGR) | 6.20%(2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Treatment Type,End-User, and Region |
| Geographies Covered | North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Â Incyte (US), Koninklijke Philips N.V. (Netherlands), Bausch Health Companies Inc. (Canada), Dr. Reddy's Laboratories Ltd. (India), STRATA Skin Sciences(US), Clinuvel Pharmaceuticals Ltd (Australia), Roivant Sciences Ltd. (Switzerland), ISSAR Pharmaceuticals Pvt. Ltd.(India) Kernel Medical Equipment Co., LTD. (China), and LightSource (US). |
| Key Market Opportunities | Rising number of clinical trials |
| Key Market Dynamics | The growing importance of aesthetic appeal and awareness. Increasing prevalence of vitiligo |
Vitiligo Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The Vitiligo Treatment market size was valued at USD 1.5 Billion in 2022.
The market is projected to grow at a CAGR of 6.20% during the forecast period, 2023-2032.
North America had the largest share of the market
The key players in the market areIncyte (US), Koninklijke Philips N.V. (Netherlands), Bausch Health Companies Inc. (Canada), Dr. Reddy's Laboratories Ltd. (India), STRATA Skin Sciences (US), Clinuvel Pharmaceuticals Ltd (Australia), Roivant Sciences Ltd. (Switzerland), ISSAR Pharmaceuticals Pvt. Ltd.(India).
The Non-segmental Vitiligo Treatment category dominated the market in 2022.
Hospitals had the largest share of the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
